{
    "clinical_study": {
        "@rank": "117663", 
        "arm_group": [
            {
                "arm_group_label": "Ipilimumab + Vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks."
            }, 
            {
                "arm_group_label": "FOLFIRINOX", 
                "arm_group_type": "Experimental", 
                "description": "Administered every 14 days (one cycle)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will enroll patients who have metastatic pancreatic cancer with stable disease on\n      FOLFIRINOX chemotherapy.  The main purpose of this study is to compare survival between\n      patients that receive ipilimumab and a pancreatic tumor vaccine and patients who continue to\n      receive FOLFIRINOX.\n\n      Funding Source - FDA OOPD"
        }, 
        "brief_title": "A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer", 
        "condition": "Metastatic Pancreatic Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (abbreviated):\n\n          1. Documented adenocarcinoma of the pancreas\n\n          2. Stable metastatic pancreatic cancer after 8-12 doses of FOLFIRINOX\n\n          3. ECOG performance status of 0 or 1\n\n          4. Life expectancy greater than 3 months\n\n          5. Adequate organ and marrow function defined by study-specified laboratory tests.\n\n          6. Must use acceptable form of birth control while on study\n\n          7. Oxygen saturation on room air >92%\n\n        Exclusion Criteria (abbreviated):\n\n          1. Surgery within 4 weeks of dosing investigational agent (some exceptions for minor\n             procedures)\n\n          2. Off FOLFIRINOX treatment for more than 49 days prior to treatment on study\n\n          3. Prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX or\n             adjuvant therapy).\n\n          4. History of prior treatment with ipilimumab, anti-PD1 antibody, CD137 agonist, or\n             anti-CD40 antibody\n\n          5. Received any non-oncology live vaccine therapy up to one month prior to or after any\n             dose of ipilimumab/vaccine\n\n          6. Receiving any other investigational agents\n\n          7. Any of the following concomitant therapy: IL-2, interferon, immunosuppressive agents,\n             or chronic use of systemic corticosteroids\n\n          8. History of symptomatic autoimmune disease or immune impairment. Thyroid disease is\n             allowed.\n\n          9. Known brain metastasis\n\n         10. Radiographic ascites that is apparent on physical exam or requiring intervention in\n             the 2 months prior to enrollment\n\n         11. Uncontrolled intercurrent illness\n\n         12. Known or suspected hypersensitivity to GM-CSF\n\n         13. Weight > or = 125 kg\n\n         14. Chronic HIV, Hepatitis B or Hepatitis C\n\n         15. Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896869", 
            "org_study_id": "J13108", 
            "secondary_id": [
                "NA_00086350", 
                "FD-R-004819-01"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Ipilimumab + Vaccine", 
                "description": "10mg/kg administered IV", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MDX-010", 
                    "BMS-734016"
                ]
            }, 
            {
                "arm_group_label": "Ipilimumab + Vaccine", 
                "description": "5x10^8 cells administered in 6 intradermal injections", 
                "intervention_name": "Vaccine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "PANC 6.03 pcDNA-1/GM-Neo and PANC 10.05 pcDNA-1/GM-Neo", 
                    "Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX)"
                ]
            }, 
            {
                "arm_group_label": "FOLFIRINOX", 
                "description": "Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.", 
                "intervention_name": "FOLFIRINOX", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pancreatic Cancer", 
            "Vaccine", 
            "Immunotherapy", 
            "Ipilimumab", 
            "CTLA-4", 
            "antibody", 
            "FOLFIRINOX"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "jhcccro@jhmi.edu", 
                "last_name": "SKCCC - Clinical Trials Office", 
                "phone": "410-955-8804"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "investigator": {
                "last_name": "Dung Le, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", 
            "last_name": "Dung Le, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison of overall survival between patients on Arm A (Vaccine + IPI) and Arm B (FOLFIRINOX)", 
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896869"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of adverse events as a measure of toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "Average time from start of treatment to progression or death, whichever comes first.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed weeks 1, 10, and 18, then every 8 weeks for up to 4 years"
            }, 
            {
                "description": "Average time from start of treatment to progression or death, whichever comes first. New lesions contribute to tumor burden, but do not by themselves qualify as progressive disease.", 
                "measure": "immune-related Progression Free Survival (irPFS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed weeks 1, 10, and 18, then every 8 weeks for up to 4 years"
            }, 
            {
                "description": "Evaluation of percentage of patients from each group Achieving a Complete Response (CR) or Partial Response (PR) by RECIST and immune-related response criteria (irRC).", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Assessed weeks 1, 10, and 18, then every 8 weeks for up to four years"
            }, 
            {
                "description": "Average length of time between achieving a complete response (CR) or partial response (PR)and documentation of recurrent or progressive disease.", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Assessed weeks 1, 10, and 18, then every 8 weeks for up to four years"
            }, 
            {
                "measure": "Tumor Marker (CA19-9) Kinetics", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 3-4 weeks for up to four years"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}